| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ECI.12.19 |
| P698 | PubMed publication ID | 22607178 |
| P2093 | author name string | Andrea Barranjard Vannucci Lomonte | |
| Cristiano A F Zerbini | |||
| P2860 | cites work | Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis | Q38274571 |
| Cadherin-11 in synovial lining formation and pathology in arthritis | Q40178718 | ||
| Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction | Q41927546 | ||
| Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta | Q42096868 | ||
| Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor | Q44639305 | ||
| The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models | Q44695040 | ||
| Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial | Q44930010 | ||
| Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates | Q46428222 | ||
| Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates | Q46868410 | ||
| Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. | Q51866375 | ||
| Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. | Q54683529 | ||
| Janus kinases in immune cell signaling | Q24322021 | ||
| Regulatory T cells in rheumatoid arthritis | Q24816793 | ||
| Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6 | Q27661705 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins | Q27860890 | ||
| A quantitative analysis of kinase inhibitor selectivity | Q28264038 | ||
| A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage | Q28287540 | ||
| Evolving concepts of rheumatoid arthritis | Q29618020 | ||
| Phenotypic and functional features of human Th17 cells | Q29619323 | ||
| Jaks and STATs: biological implications | Q29619657 | ||
| New insights into the regulation of T cells by gamma(c) family cytokines | Q33623326 | ||
| Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists [...] | Q33665938 | ||
| Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection | Q33755282 | ||
| Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis | Q34084020 | ||
| Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). | Q34169114 | ||
| Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. | Q34288951 | ||
| Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). | Q34506884 | ||
| The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo | Q34989826 | ||
| Regulation of JAK-STAT signalling in the immune system | Q35605437 | ||
| Cytokine networks--towards new therapies for rheumatoid arthritis | Q36577367 | ||
| Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis | Q36927749 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| tofacitinib | Q3530324 | ||
| P304 | page(s) | 319-331 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Tofacitinib for the treatment of rheumatoid arthritis | |
| P478 | volume | 8 |
| Q30243911 | Biologic therapies and bone loss in rheumatoid arthritis. |
| Q37552226 | Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: A case report and review of the literature |
| Q38129724 | Cell-signaling therapy in rheumatoid arthritis |
| Q45332740 | Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes |
| Q37626617 | Intracellular Signaling Pathways in Rheumatoid Arthritis |
| Q38751230 | JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. |
| Q99240942 | JAK/STAT pathway in pathology of rheumatoid arthritis (Review) |
| Q38097866 | JNK inhibitors as anti-inflammatory and neuroprotective agents |
| Q54349188 | Jak2 inhibitor--a jackpot for pharmaceutical industries: a comprehensive computational method in the discovery of new potent Jak2 inhibitors. |
| Q42537908 | Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib |
| Q34529981 | Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis. |
| Q37106758 | Pharmacotherapy options in rheumatoid arthritis |
| Q38071651 | Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present). |
| Q44911053 | Report of the second joint meeting of ESOT and AST: current pipelines in biotech and pharma |
| Q39027675 | Targeting Inflammation in Cancer Prevention and Therapy |
| Q34858352 | The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis |
| Q55487787 | The role of the JAK/STAT signal pathway in rheumatoid arthritis. |
| Q34357184 | Tofacitinab in renal transplantation. |
| Q24198120 | Tofacitinib for rheumatoid arthritis |
| Q58802123 | Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses |
| Q42160873 | tert-Butyl N-[(3R,4R)-1-(2-cyano-acet-yl)-4-methyl-piperidin-3-yl]-N-methyl-carbamate. |
Search more.